Abeona Therapeutics Welcomes Mohamad Tabrizi as Chief Business Officer
Abeona Therapeutics Inc. (Nasdaq: ABEO) is thrilled to announce the appointment of Mohamad Tabrizi as its Chief Business Officer. In this pivotal role, Tabrizi will spearhead the company's corporate strategy and oversee various business development activities. He aims to elevate operational efficiency within the organization to foster growth and innovation.
Leadership Experience of Mohamad Tabrizi
Vish Seshadri, the Chief Executive Officer of Abeona, expressed enthusiasm regarding Tabrizi's extensive expertise in strategic planning and business development. "His rich background and vast network can significantly propel Abeona forward as we strive for value-driven partnerships and greater operational success," Seshadri conveyed.
Transition from Venture Capital to Abeona
Tabrizi is making a significant transition from the venture capital sphere, having previously held prominent roles at Pandect Bioventures and the Berkeley Catalyst Fund. His leadership experience encompasses extensive investment activities and portfolio management, enhancing value creation for numerous portfolio companies.
Proven Track Record in Corporate Development
Prior to this, Tabrizi excelled as Executive Director of Corporate Business Development at Nektar Therapeutics, where he successfully managed over 20 transactions with several high-profile pharmaceutical partners, including AstraZeneca and Pfizer, over a decade-long tenure. His proven acumen in corporate development remains a tremendous asset for Abeona as it continues to innovate.
Tabrizi’s academic credentials are equally impressive; he possesses an M.B.A. from Cornell University, a master’s in Biological Sciences from Stanford University, and a bachelor’s degree in Genetics from the University of California, Davis. His diverse background blends rigorous scientific preparation with business leadership, allowing him to navigate both realms effectively.
About Abeona Therapeutics
Abeona Therapeutics is a trailblazer in the biopharmaceutical industry, dedicated to developing groundbreaking cell and gene therapies aimed at treating severe diseases. One of the company's notable innovations, ZEVASKYN (prademagene zamikeracel), holds the distinction of being the first approved autologous cell-based gene therapy for treating wounds in individuals with recessive dystrophic epidermolysis bullosa (RDEB).
Manufacturing and Research Capabilities
Situated in Cleveland, Ohio, Abeona maintains a fully integrated cell and gene therapy cGMP manufacturing facility to ensure robust, scalable production of ZEVASKYN. Furthermore, the company is at the forefront of developing adeno-associated virus (AAV)-based therapies targeting urgent unmet medical needs, demonstrating a strong commitment to innovative healthcare solutions.
Future Vision of Abeona
Looking ahead, Abeona is actively exploring novel AAV capsid technologies for a range of debilitating conditions. The company aims to maintain its pivotal role in the dynamic field of biotechnology and continue pushing the boundaries of therapeutic possibilities.
Frequently Asked Questions
Who is Mohamad Tabrizi?
Mohamad Tabrizi is the newly appointed Chief Business Officer at Abeona Therapeutics, bringing extensive experience in business development and corporate strategy.
What is ZEVASKYN?
ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
Where is Abeona Therapeutics located?
Abeona Therapeutics is headquartered in Cleveland, Ohio, where it operates a state-of-the-art manufacturing facility.
What is the primary focus of Abeona Therapeutics?
Abeona is focused on developing innovative cell and gene therapies for serious diseases, showcasing a commitment to addressing significant healthcare challenges.
How can I learn more about Abeona Therapeutics?
For further information, please visit the official Abeona Therapeutics website.
